Literature DB >> 31700627

Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis.

Fernando Magro1,2,3, Maria Manuela Estevinho1.   

Abstract

Entities:  

Year:  2019        PMID： 31700627      PMCID： PMC6826531          DOI： 10.1177/2050640619878588

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  13 in total

1.  Management of Crohn's disease - are guidelines transferred to clinical practice?

Authors:  Thomas Klag; Eduard F Stange; Jan Wehkamp
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

Review 2.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

3.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

Authors:  William J Sandborn; Simon Travis; Luigi Moro; Richard Jones; Theres Gautille; Robert Bagin; Michael Huang; Phil Yeung; E David Ballard
Journal:  Gastroenterology       Date:  2012-08-11       Impact factor: 22.682

4.  Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

Authors:  Nghia H Nguyen; Mathurin Fumery; Parambir S Dulai; Larry J Prokop; William J Sandborn; Mohammad Hassan Murad; Siddharth Singh
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-08-17

5.  Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.

Authors:  Stefanos Bonovas; Georgios K Nikolopoulos; Daniele Piovani; Marien González-Lorenzo; Katerina Pantavou; Theodore Lytras; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Br J Clin Pharmacol       Date:  2019-07-31       Impact factor: 4.335

6.  Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.

Authors:  David Marti-Aguado; María Pilar Ballester; Joan Tosca; Marta Maia Bosca-Watts; Pablo Navarro; Rosario Anton; Isabel Pascual; Francisco Mora; Miguel Minguez
Journal:  United European Gastroenterol J       Date:  2019-05-29       Impact factor: 4.623

7.  Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Authors:  Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2017-03-30       Impact factor: 4.623

8.  Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Authors:  David T Rubin; Russell D Cohen; William J Sandborn; Gary R Lichtenstein; Jeffrey Axler; Robert H Riddell; Cindy Zhu; Andrew C Barrett; Enoch Bortey; William P Forbes
Journal:  J Crohns Colitis       Date:  2017-07-01       Impact factor: 9.071

9.  Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.

Authors:  W J Sandborn; S Danese; G D'Haens; L Moro; R Jones; R Bagin; M Huang; E David Ballard; J Masure; S Travis
Journal:  Aliment Pharmacol Ther       Date:  2015-01-15       Impact factor: 8.171

10.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

Authors:  Marcus Harbord; Rami Eliakim; Dominik Bettenworth; Konstantinos Karmiris; Konstantinos Katsanos; Uri Kopylov; Torsten Kucharzik; Tamás Molnár; Tim Raine; Shaji Sebastian; Helena Tavares de Sousa; Axel Dignass; Franck Carbonnel
Journal:  J Crohns Colitis       Date:  2017-07-01       Impact factor: 10.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.